Regulation of Fas-mediated apoptosis by N-ras in melanoma

Journal of Investigative Dermatology

Volumn 119, Issue 3, 2002, Pages 556-561

  Urquhart, Jean L ^a   Meech, Sandra J ^b   Marr, David G ^a   Shellman, Yiqun G ^a   Duke, Richard C ^c   Norris, David A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BROWN UNIVERSITY   (United States)

^c Ceres Pharmaceuticals Ltd   (United States)

Author keywords

Fas ligand; FLIP; FT1 277

Indexed keywords

CHROMIUM 51; FAS ANTIGEN; FAS LIGAND; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 0036379395     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.01854.x     Document Type: Article

References (35)

1. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP: Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 102:285-290, 1994
2. Behrmann I, Walczak H, Krammer PH: Structure of the human APO-1 gene. Eur J Immunol 24:3057-3062, 1994
3. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 377:630-632, 1995
4. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 270:7795-7798, 1995
5. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP: Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 59:59-62, 1999
6. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505-512, 1995
7. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A: The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025-1032, 1999
8. Duke RC, Newell E, Schleicher M, Meech S, Bellgrau D: Transplantation of cells and tissues expressing Fas ligand. Transplant Proc 31:1479-1481, 1999
9. Evan G, Littlewood T: A matter of life and cell death. Science 281:1317-1322, 1998
10. Fenton RG, Hixon JA, Wright PW, Brooks AD, Sayers TJ: Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res 58:3391-3400, 1998
11. French LE, Tschopp J: Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med 190:891-894, 1999
12. Fujita M, Norris DA, Yagi H, et al: Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo. Melanoma Res 9:279-291, 1999
13. Gibbs JB, Pompliano DL, Mosser SD, et al: Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620, 1993
14. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995
15. Hahne M, Rimoldi D, Schroter M, et al: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366, 1996
16. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM: I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 272:17255-17257, 1997
17. Irmler M, Thome M, Hahne M, et al: Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195, 1997
18. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G: Suppression of c-Myc-induced apoptosis by Ras signalling through PI (3) K and PKB. Nature 385:544-548, 1997
19. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. Embo J 16:2783-2793, 1997
20. Kohl NE, Wilson FR, Mosser SD, et al: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91:9141-9145, 1994
21. Kohl NE, Wilson FR, Thomas TJ, Bock RL, Mosser SD, Oliff A, Gibbs JB: Inhibition of Ras function in vitro and in vivo using inhibitors of farnesyl-protein transferase. Meth Enzymol 255:378-386, 1995
22. Lerner EC, Qian Y, Blaskovich MA, et al: Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-26806, 1995
23. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501, 1998
24. Lowe SW, Lin AW: Apoptosis in cancer. Carcinogenesis 21:485-495, 2000
25. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R: Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190:1033-1038, 1999
26. Nagata S: Apoptosis by death factor. Cell 88:355-365, 1997
27. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54:1580-1586, 1994
28. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J: Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. Embo J 18:1824-1831, 1999
29. Sebti SM, Hamilton AD: Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:6584-6593, 2000
30. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85:757-764, 1995
31. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179:873-879, 1994
32. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178, 1993
33. Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U: Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 82:727-736, 1999
34. Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158:4521-4524, 1997
35. Yang BC, Wang YS, Liu HS, Lin SJ: Ras signaling is involved in the expression of Fas-L in glioma. Lab Invest 80:529-537, 2000